Clinical trial
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI)…
NCT00448721 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00448721 |
|---|---|
| Title | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer |
| Official title | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | AEterna Zentaris, Industry |
| Collaborators | Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Perifosine |
| Enrollment | 24 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Mar 19, 2007 |
| Last update posted | Mar 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: